The utility of Aspirin in dukes C and high risk dukes B colorectal cancer - The ASCOLT study: Study protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Ali, Raghib ^a   Toh, Han Chong ^b   Chia, Whay Kuang ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Adjuvant; Ascolt; Aspirin; Cancer; Colon; Dukes b; Dukes c; Inflammation; Platelets; Rectal

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; CYCLOOXYGENASE 2 INHIBITOR;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE FREE SURVIVAL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EAR DISEASE; EAR RINGING; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; SAMPLE SIZE;

ASPIRIN; CLINICAL PROTOCOLS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; SAMPLE SIZE;

EID: 83355163988     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-261     Document Type: Article

References (48)

1. Cancer Incidence, Mortality, and Prevalence Worldwide. GLOBOCAN 2000, American Cancer Society.
2. Sung JJ, Lau YW, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005, 6:871-76. 10.1016/S1470-2045(05)70422-8, 16257795.
3. Singapore Cancer Registry Interim Report: Trends in Cancer Incidence in Singapore 2002-2006. National Registry of Disease Office (NRDO)
4. Boyle P, Levin B. WHO 2008 World cancer Report. International Agency for Research on Cancer. Nonserial Publication, WHO Press 2008,
5. Ali R, Raina V. Developing innovative models for North-South cooperation in clinical research - experience from the INDOX Cancer Research Network. Annals of Oncology 2008, 19:831-833. 10.1093/annonc/mdn034, 18325920.
6. Cavalli F. Cancer in the developing world: Can we avoid the disaster?. Nat Clin Prac Oncol 2006, 3(11):583-3.
7. Wolmark N, Fisher B, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80(1):30-6. 10.1093/jnci/80.1.30, 3276901.
8. Moertel CG, Fleming TR, Macdonald JS, Haller DJ, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillaird JA. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122(5):321-6.
9. O'Connell MJ, Mailliard JA, Kahn MJ, Haller DJ, Mayer RJ, Wieand HS. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15(1):246-50.
10. Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005, 23(9):1819-25. 10.1200/JCO.2005.04.169, 15774775.
11. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352(26):2696-704. 10.1056/NEJMoa043116, 15987918.
12. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Rabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350(23):2343-51. 10.1056/NEJMoa032709, 15175436.
13. Van Cutsem E, Labianca R, Hossfeld D. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients. (PETACC 3). J Clinl Oncol 2005, 23(16S):8.
14. Ychou M, Raoul J-L, Douillard J-Y. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol 2005, 23(16S):3502.
15. Saltz LB, Niedzwiecki D, Hollis D. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol 2004, 22(14S):3500.
16. Chau I, Cunningham D. Adjuvant chemotherapy for colon cancer - what, when and how. Ann Oncol 2006, 9:1347-59.
17. Berges G, Benjamin LE. Tumorigenesis and the Angiogenic Switch. Nat Rev Cancer 2003, 3(6):401-10. 10.1038/nrc1093, 12778130.
18. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Goldberg RM, Chu L, Azar CA, Lopa S, Wolmark N. Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. J Clin Oncol 2011, 29:11-16. 10.1200/JCO.2010.30.0855, 20940184.
19. Alberts SR, Sargent DJ, Smyrk TC. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 2010, 28(15s):3507.
20. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1999, 18:7908-16.
21. Cai QY, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, Wen W, Rothman N, Li HL, Morrow JD, Zheng W. Prospective Study of Urinary Prostaglandin E2 Metabolite and Colorectal Cancer Risk. J Clin Oncol 2006, 24:5010-5016. 10.1200/JCO.2006.06.4931, 17075120.
22. Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon. Study code: NCT00085163., http://www.clinicaltrials.gov
23. Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer. Study code: NCT00031863., http://www.clinicaltrials.gov
24. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iverson C, Yanagisawa Y, Warren B, Langman MJ, Kerr D. Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial. J Clin Oncol 2010, (28):4575-4580.
25. Fuchs C, Meyerhardt D, Heseltine L. Influence of regular Aspirin on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol 2005, 23S:3530.
26. Chan AT, Ogino S, Fuchs C. Aspirin use and survival after the diagnosis of Colorectal cancer. JAMA 2009, 302(6):649-659. 10.1001/jama.2009.1112, 2848289, 19671906.
27. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006, 119(8):624-38. 10.1016/j.amjmed.2005.10.039, 16887404.
28. Impreriale TF. Aspirin and the Prevention of colorectal cancer. N Engl J Med 2003, 348(10):879-880. 10.1056/NEJMp030005, 12621130.
29. Kune GA, Kune S, Watson LF. Colorectal Cancer Risk, Chronic Illnesses, Operations and Medications: Case Control Results from the Melbourne Colorectal Cancer Study. Cancer Res 1988, 48(15):4399-404.
30. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin Use and Risk of Fatal Cancer. Cancer Res 1993, 53(6):1322-7.
31. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5(2):138-46. 10.1097/00001648-199403000-00003, 8172988.
32. Giovannucci E, Edgan KM, Hunter D, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of Colorectal cancer in women. N Engl J Med 1995, 333(10):609-14. 10.1056/NEJM199509073331001, 7637720.
33. Flossmann E, Rothwell PM. Effect of Aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-13. 10.1016/S0140-6736(07)60747-8, 17499602.
34. Thun MJ, Henley SJ, Patrono C. Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. J Natl Cancer Inst 2002, 94:252-66.
35. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993, 14(8):1493-7. 10.1093/carcin/14.8.1493, 8353834.
36. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980, 64(12):1323-7.
37. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981, 41(5):1954-7.
38. Tsujii M, Kawano, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells. Cell 1998, 93:705-16. 10.1016/S0092-8674(00)81433-6, 9630216.
39. Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004, 10(13):1971-4.
40. Schwertfeger KL, Xian W, Kaplan AM, Burnett SH, Cohen DA, Rosen JM. A Critical Role for the Inflammatory Response in a Mouse Model of Preneoplastic Progression. Cancer Res 2006, 66(11):5676-85. 10.1158/0008-5472.CAN-05-3781, 16740705.
41. Mantovani A. Inflaming metastasis. Nature 2009, 457:36-7.
42. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310(5753):1504-10. 10.1126/science.1116221, 16293724.
43. Jinyi S, Chaeyong J, Chunming L. Prostaglandin E2 stimulates the b-catenin/T Cell Factor-dependent Transcription in colon cancer. J Bio Chem 2005, 28:26565-72.
44. Cai Q, Gao YT, Chow WH, Shu XO, Yang G, Ji BT, Wen W, Rothman N, Li HL, Morrow JD, Zheng W. Prospective Study of Urinary Prostaglandin E2 Metabolite and Colorectal Cancer Risk. J Clin Oncol 2006, 24:5010-16. 10.1200/JCO.2006.06.4931, 17075120.
45. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41. 10.1016/S0140-6736(10)62110-1, 21144578.
46. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, andel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A Randomised Trial of Aspirin to Prevent Colorectal Adenomas. N Engl J Med 2003, 348:891-9. 10.1056/NEJMoa021735, 12621133.
47. Ruffin MT, Krishnan K, Rock CL. Supression of human colorectal mucosal prostaglandins: determining the lowest effective Aspirin dose. J Natl Cancer Inst 1997, 89(15):1152-60. 10.1093/jnci/89.15.1152, 9262254.
48. Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, Do KA, Sinicrope FA. A dose-finding study of Aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 2002, 11(3):275-9.